DrugMay 27, 2026
Primidone Tablets, USP, 50 mg, 100 Tablets recall — FDA D-0537-2026
Cross contamination with other products: API contaminated with trace amounts of Acemetacin API.
Class IIIFDA: OngoingAmerisource Health Services LLC
Recall history in this database
Classification mix: Class II: 15, Class III: 2.
DrugMay 27, 2026
Primidone Tablets, USP, 250 mg, 100 Tablets recall — FDA D-0536-2026
Cross contamination with other products: API contaminated with trace amounts of Acemetacin API.
Class IIIFDA: OngoingAmerisource Health Services LLC
DrugFeb 18, 2026
Oxycodone Hydrochloride Tablets, USP (CII), 5 mg, 100-Count (10 x 10) blister cards per recall — FDA D-0338-2026
Defective container: card seal defects (weak/non-existent seals), leading to the tablets falling out of their cavities.
Class IIFDA: OngoingAmerisource Health Services LLC
DrugNov 5, 2025
Prazosin Hydrochloride, Capsules, USP, 5 mg, 20 capsules (5x4) cartons recall — FDA D-0103-2026
Failed Impurities/Degradation Specification: presence of N-nitroso Prazosin impurity C above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit
Class IIFDA: OngoingAmerisource Health Services LLC
DrugNov 5, 2025
Prazosin Hydrochloride, Capsules, USP, 2 mg, 100 capsules (10x10) cartons recall — FDA D-0102-2026
Failed Impurities/Degradation Specification: presence of N-nitroso Prazosin impurity C above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit
Class IIFDA: OngoingAmerisource Health Services LLC
DrugNov 5, 2025
Prazosin Hydrochloride, Capsules, USP, 1 mg, 100 capsules (10x10) cartons recall — FDA D-0101-2026
Failed Impurities/Degradation Specification: presence of N-nitroso Prazosin impurity C above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit
Class IIFDA: OngoingAmerisource Health Services LLC
DrugOct 22, 2025
Amerisource Health Services Sucralfate Tablets, USP 1 gram, 100 Tablets, (10x10) recall — FDA D-0027-2026
CGMP Deviations: The recalling firm filed for Chapter 11 on September 30, 2024. As a result, it cannot monitor the quality program and hence cannot assure that products meet the identity,…
Class IIFDA: OngoingAmerisource Health Services LLC
DrugSep 24, 2025
chlorproMAZINE Hydrochloride Tablets, USP, 200 mg, 100 (10x10) blisterpack per carton recall — FDA D-0650-2025
Presence of a foreign substance.A specific lot of auxiliary polyester coil, used in product packaging at the manufacturing site, was detected with presence of a micro-organism. No…
Class IIFDA: OngoingAmerisource Health Services LLC
DrugSep 24, 2025
chlorproMAZINE Hydrochloride Tablets, USP, 50 mg, 100 (10x10) blisterpacks recall — FDA D-0648-2025
Presence of a foreign substance.A specific lot of auxiliary polyester coil, used in product packaging at the manufacturing site, was detected with presence of a micro-organism. No…
Class IIFDA: OngoingAmerisource Health Services LLC
DrugSep 24, 2025
chlorproMAZINE Hydrochloride Tablets, USP, 100 mg, 100 (10x10) blisterpack per carton recall — FDA D-0649-2025
Presence of a foreign substance.A specific lot of auxiliary polyester coil, used in product packaging at the manufacturing site, was detected with presence of a micro-organism. No…
Class IIFDA: OngoingAmerisource Health Services LLC
DrugSep 24, 2025
chlorproMAZINE Hydrochloride Tablets, USP, 25 mg, packaged as a) 50 (5x10) blisterpacks recall — FDA D-0647-2025
Presence of a foreign substance.A specific lot of auxiliary polyester coil, used in product packaging at the manufacturing site, was detected with presence of a micro-organism. No…
Class IIFDA: OngoingAmerisource Health Services LLC
DrugSep 3, 2025
Amerisource Health Services Sucralfate Tablets, USP 1 gram, 100 Tablets, (10x10) recall — FDA D-0598-2025
CGMP Deviations: The recalling firm filed for Chapter 11 in September 2024. As a result, it cannot monitor the quality program and hence cannot assure that products meet the identity,…
Class IIFDA: OngoingAmerisource Health Services LLC
DrugApr 30, 2025
Haloperidol Decanoate Injection, 100 mg/mL*, 1 x 1 mL Single-Dose Vial recall — FDA D-0368-2025
Lack of assurance of sterility. Bacterial contamination detected in some media fill units
Class IIFDA: OngoingAmerisource Health Services LLC
DrugApr 30, 2025
Haloperidol Decanoate Injection, 100mg/mL*, 5 x 1 mL Single-Dose Vials recall — FDA D-0369-2025
Lack of assurance of sterility. Bacterial contamination detected in some media fill units
Class IIFDA: OngoingAmerisource Health Services LLC
DrugApr 30, 2025
Haloperidol Decanoate Injection, 50mg/mL* , 1 mL Single-Dose Vial recall — FDA D-0367-2025
Lack of assurance of sterility. Bacterial contamination detected in some media fill units
Class IIFDA: OngoingAmerisource Health Services LLC
DrugApr 9, 2025
Voriconazole Tablets, 50 mg recall — FDA D-0307-2025
cGMP Deviations: Received notification from their supplier requesting they perform a recall due to the fact they repackaged the product.
Class IIFDA: TerminatedAmerisource Health Services LLC
DrugDec 11, 2024
Amerisource Health Services Duloxetine Delayed-Release Capsules, USP, 30 mg recall — FDA D-0100-2025
CGMP Deviations: Presence of N-nitroso-duloxetine impurity above the recommended interim limit
Class IIFDA: OngoingAmerisource Health Services LLC
Understanding this recall history
This page summarizes recall records in which the official source identifies Amerisource Health Services LLC as the recalling firm or manufacturer. The number of records should not be treated as a safety rating or a measure of company size, because recall counts depend on product mix, reporting periods and how government records are organized.
Compare the dates, categories and classifications together rather than relying on the total alone. Open an individual record for the recalled product, reason, distribution details and current instructions available from the source.